Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA.

Yeh SH, Lin CF, Kong FL, Wang HE, Hsieh YJ, Gelovani JG, Liu RS.

Biomed Res Int. 2013;2013:549359. doi: 10.1155/2013/549359. Epub 2013 Jul 17.

2.

Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.

Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, Shavrin A, Soghomonyan S, Flores L 2nd, Young D, Volgin AY, Najjar AM, Krasnykh V, Tong W, Alauddin MM, Gelovani JG.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1603-8. doi: 10.1073/pnas.1010744108. Epub 2011 Jan 10.

3.

Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.

Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, Finn R, Larson SM, Bornmann W, Gelovani JG.

Mol Imaging Biol. 2006 Sep-Oct;8(5):262-77. Erratum in: Mol Imaging Biol. 2006 Nov-Dec;8(6):373. Namavari, Mohammed [added].

PMID:
16897320
4.

Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.

Pal A, Balatoni JA, Mukhopadhyay U, Ogawa K, Gonzalez-Lepera C, Shavrin A, Volgin A, Tong W, Alauddin MM, Gelovani JG.

Mol Imaging Biol. 2011 Oct;13(5):853-61. doi: 10.1007/s11307-010-0408-8.

PMID:
20859697
5.

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.

Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R.

Mol Cancer Ther. 2009 Jun;8(6):1536-46. doi: 10.1158/1535-7163.MCT-08-0978. Epub 2009 Jun 9.

6.

TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Otani H, Yamamoto H, Takaoka M, Sakaguchi M, Soh J, Jida M, Ueno T, Kubo T, Asano H, Tsukuda K, Kiura K, Hatakeyama S, Kawahara E, Naomoto Y, Miyoshi S, Toyooka S.

PLoS One. 2015 Jun 19;10(6):e0129838. doi: 10.1371/journal.pone.0129838. eCollection 2015.

7.

Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.

Yoshimoto M, Hirata M, Kanai Y, Naka S, Nishii R, Kagawa S, Kawai K, Ohmomo Y.

Biol Pharm Bull. 2014;37(3):355-60.

8.

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.

Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.

Oncol Rep. 2013 May;29(5):1975-82. doi: 10.3892/or.2013.2298. Epub 2013 Feb 21.

PMID:
23440266
9.

Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.

Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.

Cell Death Dis. 2015 Aug 6;6:e1850. doi: 10.1038/cddis.2015.217.

10.

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.

12.

Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.

Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, Aikawa E, Abe H, Yamaguchi T, Takamori S, Akiba J, Kage M.

Lung Cancer. 2011 Oct;74(1):35-40. doi: 10.1016/j.lungcan.2011.02.002. Epub 2011 Mar 27.

PMID:
21444121
13.

Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.

Bessette DC, Tilch E, Seidens T, Quinn MC, Wiegmans AP, Shi W, Cocciardi S, McCart-Reed A, Saunus JM, Simpson PT, Grimmond SM, Lakhani SR, Khanna KK, Waddell N, Al-Ejeh F, Chenevix-Trench G.

PLoS One. 2015 May 13;10(5):e0125232. doi: 10.1371/journal.pone.0125232. eCollection 2015.

14.

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.

Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR.

J Thorac Oncol. 2010 Oct;5(10):1551-8. doi: 10.1097/JTO.0b013e3181e9da60.

15.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, BarĂ³n A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

16.

EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.

Yang CH, Chou HC, Fu YN, Yeh CL, Cheng HW, Chang IC, Liu KJ, Chang GC, Tsai TF, Tsai SF, Liu HP, Wu YC, Chen YT, Huang SF, Chen YR.

Biochim Biophys Acta. 2015 Jul;1852(7):1540-9. doi: 10.1016/j.bbadis.2015.04.020. Epub 2015 Apr 23.

17.

Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.

Verone-Boyle AR, Shoemaker S, Attwood K, Morrison CD, Makowski AJ, Battaglia S, Hershberger PA.

Oncotarget. 2016 Jan 5;7(1):995-1013. doi: 10.18632/oncotarget.6493.

18.

Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells.

Hung MS, Chen IC, Lung JH, Lin PY, Li YC, Tsai YH.

PLoS One. 2016 Jun 30;11(6):e0158395. doi: 10.1371/journal.pone.0158395. eCollection 2016.

19.

Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer.

Valley CC, Arndt-Jovin DJ, Karedla N, Steinkamp MP, Chizhik AI, Hlavacek WS, Wilson BS, Lidke KA, Lidke DS.

Mol Biol Cell. 2015 Nov 5;26(22):4087-99. doi: 10.1091/mbc.E15-05-0269. Epub 2015 Sep 2.

20.

Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.

Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M.

Cancer Sci. 2009 Aug;100(8):1526-31. doi: 10.1111/j.1349-7006.2009.01197.x. Epub 2009 May 13.

Supplemental Content

Support Center